Taysha Gene Therapies (TSHA) IPO Opens 11% Higher

Today's IPO for Taysha Gene Therapies, Inc. (NASDAQ: TSHA) opened for trading at $22.25 after pricing 7,869,566 shares of common stock at a price to the public of $20.00 per share.

Goldman Sachs & Co. LLC, Morgan Stanley and Jefferies are acting as joint book-running managers for the offering. Chardan is acting as lead manager for the offering.

Taysha Gene Therapies, Inc. is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations.

You May Also Be Interested In

• ADARx Pharmaceuticals files for proposed IPO
• Evercore sees strong jobs data not altering Fed September call
• USA Rare Earth completes merger with Serra Verde Group